Myosin activator omecamtiv mecarbil exhibits divergent inotropic and lusitropic effects in cardiac slices from patients with heart failure

[1]  N. D. de Groot,et al.  Omecamtiv mecarbil in precision-cut living heart failure slices: A story of a double-edged sword , 2023, Journal of Molecular and Cellular Cardiology Plus.

[2]  Sheng-Nan Wu,et al.  Characterization of Stimulatory Action on Voltage-Gated Na+ Currents Caused by Omecamtiv Mecarbil, Known to Be a Myosin Activator , 2023, Biomedicines.

[3]  Z. Csanádi,et al.  Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca2+ levels , 2023, ESC heart failure.

[4]  C. Mélot,et al.  Altered Left Ventricular Rat Gene Expression Induced by the Myosin Activator Omecamtiv Mecarbil , 2023, Genes.

[5]  G. Santulli,et al.  Efficacy of the New Inotropic Agent Istaroxime in Acute Heart Failure , 2022, Journal of clinical medicine.

[6]  S. Ishiwata,et al.  Effects of omecamtiv mecarbil on the contractile properties of skinned porcine left atrial and ventricular muscles , 2022, Frontiers in Physiology.

[7]  A. Cohen-Solal,et al.  Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. , 2022, JAMA.

[8]  S. Solomon,et al.  Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. , 2021, JAMA cardiology.

[9]  B. Trimarco,et al.  Advances in the understanding of excitation-contraction coupling: The pulsing quest for drugs against heart failure and arrhythmias. , 2021, European heart journal. Cardiovascular pharmacotherapy.

[10]  Jose H. Flores-Arredondo,et al.  Effect of Ejection Fraction on Clinical Outcomes in Patients treated with Omecamtiv Mecarbil in GALACTIC-HF. , 2021, Journal of the American College of Cardiology.

[11]  S. Solomon,et al.  Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure , 2020, Circulation. Heart failure.

[12]  Piotr Ponikowski,et al.  Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial , 2016, The Lancet.

[13]  D. Mann.  Searching for the perfect agent to improve cardiac contractility , 2016, The Lancet.

[14]  Piotr Ponikowski,et al.  Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. , 2016, Journal of the American College of Cardiology.

[15]  B. Morgan,et al.  Cardiac myosin activation part 1: from concept to clinic. , 2011, Journal of molecular and cellular cardiology.

[16]  J. Cleland,et al.  The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial , 2011, The Lancet.

[17]  J. Goldman,et al.  Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study , 2011, The Lancet.

[18]  D. Cox,et al.  Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure , 2011, Science.

[19]  J. Teerlink.  A novel approach to improve cardiac performance: cardiac myosin activators , 2009, Heart Failure Reviews.

[20]  Gaetano Santulli,et al.  New Insights in Cardiac Calcium Handling and Excitation-Contraction Coupling. , 2018, Advances in experimental medicine and biology.